[2]A. Ranghiero, E. Guerini Rocco, A. Rappa, et al. Homologous recombination deficiency (HRD) testing on ovarian cancer ascites: A feasibility study. 2023 ESMO abstracts. 1223P [3]S. Kim, M-R. Han, E-Y. Oh, et a...
[4]Roussel-Simonin C, Tang R, Blanc-Durand F, et al.An evaluation of cell-free tumor DNA from 20 mL of peritoneal fluid for homologous recombination deficiency (HRD) testing in newly diagnosed ovarian cancer (OC). 20...
Background: HRD testing in ovarian cancer to date is predominately based on dichotomizing scores defining HR-deficiency and -proficiency. We herein provide a new comprehensive approach to test HR-status, which aims to assess HRD in a qualitative and quantitative manner. Methods: In addition to ...
[12] Miller, R.E., et al., ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals of Oncology, 2020. [13] BRCA数据解读中国专家共识编写组, BRCA数据解读中国专家共识. 中华病理学杂志, 2017. 46(5): p. 5....
Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. Eur J Cancer. 2023;179:136-146. doi:10.1016/j.ejca.2022.10.021. 往期精彩推荐 杰论系列 | FLT3基因突变与AML治疗 杰论系列 | 因ADC技术重获关注的...
[12] Miller, R.E., et al., ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals of Oncology, 2020. [13] BRCA数据解读中国专家共识编写组, BRCA数据解读中国专家共识. 中华病理学杂志, 2017. 46(5): p. 5....
[4] Miller, R. E. et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol 31, 1606-1622, doi:10.1016/j.annonc.2020.08.2102 (2020). [5] Gonzalez, D. & Stenzinger, A. Homologous recombination ...
The studyalso found a higher rate of HRD positivity in Chinese ovarian cancer patients than in Western populations, suggesting that HRD testing could screen a higher proportion of Chinese PARP inhibitor population to facilitate precision therapy. ...
The Role of PARP Inhibitors in Ovarian Cancer : Episode 7 Video November 27, 2019 The Importance of HRD TestingKey opinion leaders discuss the importance of HRD testing, with special consideration of tissue testing versus somatic testing.Maurie Markman, MD: We talked about BRCA mutations, which...
Our data demonstrate the feasibility of internal HRD testing by the AmoyDx HRD Focus Panel for high-grade serous ovarian cancer (HGSOC), showing results similar to other methods. The HRD rate in the Russian population is very similar to those of other European populations, as is the BRCA ...